TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06126380
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus dosed PO BID with the dose titrated to maintain a trough concentration of 6-8 ng/mL+ MMF 1000 mg PO BID or MPS 720 mg PO BID + Corticosteroids 5 mg of prednisone PO QD or equivalent
Study: NCT04781673
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Will receive titratable infusion.
Study: NCT04781673
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Will receive titratable infusion, will have daily lidocaine level labs drawn daily.
Study: NCT04990128
Drug: Triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg (1 mL) triamcinolone and 4 cc of lidocaine 1% that will be injected into the hip.
Study: NCT04887792
Drug: Acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACZ 250 mg/day in gelatin capsules will be administered initially and increased over 7-10 days to 2g/day.
Study: NCT06667765
Drug: RPT1G
Normalized name: Rifapentine 1g
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose formulation- Oral capsule
Study: NCT06215911
Drug: Tovinontrine (CRD-750)
Normalized name: Tovinontrine
DrugBank: Tovinontrine (DB16193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally
Study: NCT06798038
Drug: alcohol neurolysis
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 35 Patients will be administered with 1.0ml of 70% alcohol per genicular nerve
Study: NCT06329401
Drug: AP01
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral inhalation solution
Study: NCT04995835
Drug: Cefiderocol
Normalized name: Cefiderocol
DrugBank: Cefiderocol (DB14879)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After receipt of Cefiderocol, blood samples will be collected at various time points to determine the pharmacokinetics of Cefiderocol
Study: NCT04651088
Drug: Potassium citrate
Normalized name: Potassium Citrate
DrugBank: Potassium citrate (DB09125)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Slow release potassium citrate UroCit-K. Participants will take 20mEq twice daily.
Study: NCT04651088
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 650mg tabs. Take 3 tabs twice daily.
Study: NCT04651088
Drug: Potassium Bicarbonate
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mEq tablets, one tablet twice daily
Study: NCT05062785
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This will be given intranasally at differing doses depending on study day. A total of 11 possible doses will be tested, ranging from 0 to 1000 U insulin. Each volunteer will come for 5 visits.~On the first treatment day participants will receive placebo (sterile water) in each nostril followed by a 4-hour observation period. After this observation period participants will receive the initial dose of insulin squirted in each nostril followed by a a 4 hour observation period. Participants will have at least 7 days in between the other 4 visits. Subsequent visits will include increased doses of insulin (depending on how this is tolerated) and will take approximately 4 hours at these visits.
Study: NCT06790342
Drug: Cystine
Normalized name: Cystine
DrugBank: Cystine (DB00138)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Used for smoking cessation and alcohol reduction
Study: NCT06785285
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: To compare the effects of fentanyl and dexmedetomidine when used as adjuvants to intrathecal bupivacaine in elective cesarean section, assessing their impact on the onset and duration of spinal anesthesia, quality of analgesia, hemodynamic stability, incidence of side effects, and neonatal outcomes
Study: NCT06790732
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients received sham PENG block (just 1mL saline).
Study: NCT06790732
Drug: Bupivacaine + Dexamethasone
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients received real PENG block (15 mL of bupivacaine 0.25% +0.2mg/mL dexamethasone).
Study: NCT04943952
Drug: Asparaginase Erwinia Chrysanthemi (recombinant)
Normalized name: Asparaginase Erwinia chrysanthemi (recombinant)
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JZP458 via intramuscular injection.
Study: NCT06789107
Drug: Blinatumomab 9ug
DrugBank: Blinatumomab (DB09052)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Blinatumomab for Refractory/Active Systemic Lupus Erythematosus. Patients will receive two 5-day cycles of Blinatumomab (5 µg/m²/day, maximum dose 9 µg/day), administered intravenously. The second cycle will begin on the first day of the third week following the first cycle.
Study: NCT06790121
Drug: Lunsekimig
Normalized name: Lunsekimig
DrugBank: Lunsekimig (DB19009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for injection in vial Route of administration: Subcutaneous injection
Study: NCT06788938
Drug: Tarlatamab treatment
Normalized name: Tarlatamab
DrugBank: Tarlatamab (DB17256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * 1 mg step dose on cycle 1 day 1 (C1D1)~* 10 mg target dose on cycle 1 day 8 (C1D8), and cycle 1 day 15 (C1D15) in a 28-day cycle.~* 10 mg Q2W subsequently (i.e., C2 + D1/D15 dosing) in a 28-day cycle
Study: NCT06788431
Drug: IMC-001
Normalized name: IMC-18F1
DrugBank: Icrucumab (DB14824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive IMC-001 administered by injection once a week for 9-12 weeks.
Study: NCT06792474
Drug: Lidocaine in Saline
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine infusion 1.5 mg/kg/hr
Study: NCT06784882
Drug: single injection nerve block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An adductor canal single injection nerve block will be performed per standard of care. The adductor canal will be identified by ultrasound in the short-axis view. The distal aspect of the femoral triangle (and beginning of the adductor canal) will be identified distal to the mid-thigh in the ipsilateral limb. Using ultrasound guidance, a standard Tuohy block needle will be advanced through a skin wheal of lidocaine until its tip is in the hypoechoic area immediately distal saphenous nerve adjacent to the femoral artery. Twenty milliliters of ropivacaine 0.5% will be injected in divided doses with repeated negative aspiration.
Study: NCT06783764
Drug: bupivacaine 0.25 % injection
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: injection of 10 ml 0.25% bupivacaine between pectoralis major and minor muscles and 10 ml between the pectoralis minor and serratus anterior muscles) at the third or the fourth rib, then 10 ml between the internal inter-costal muscles and the transversus thoracic muscle
Study: NCT06783764
Drug: bupivacaine 0.25 % injection
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 ml of 0.25% bupivacaine injected deep to the erector spinae muscle at the transverse process of the fifth thoracic vertebrae
Study: NCT06783491
Drug: Mitomycin (MM)
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin 30mg/m2/4 litres of perfusion liquid (dextrose 1.5%). Single intraoperative dose.
Study: NCT06787118
Drug: CBD oil
Normalized name: MENTHOL, UNSPECIFIED FORM 10 g in 100 g / CAMPHOR (NATURAL) 3 g in 100 g TOPICAL CREAM [ETERNAL SPIRIT BEAUTY PAINLESS WITH CBD OIL 3000]
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive CBD-oral solution 2.5 mg/kg PO BID for a total of 12 weeks.
Study: NCT05301660
Drug: Nicotine transdermal patch
Normalized name: MENTHOL 0.3 g in 100 TOPICAL PATCH [Aroamas Cot Nicotine Transdermal Patches]
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14 mg / tablet, one tablet a day, attached to the patient's back for 8 weeks
Study: NCT06791434
Drug: Fixed Dose Combination Etoshine MR tablets
Normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Composition per tablet: Etoricoxib 60 mg + Thiocolchicoside 4 mg
Study: NCT05318534
Drug: GL-0719
Normalized name: GL-0719
DrugBank: GL-0719 (DB18436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration route: intravenous infusion and subcutaneous injection
Study: NCT06785987
Drug: Continuous Lidocaine Infusion
Normalized name: Ivy Dry Super Continuous Spray
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maintained with sevoflurane and continuous lidocaine infusion under dosage: 1.5 mg/kg/hr
Study: NCT06786468
Drug: Standard systemic treatment for advanced lung cancer
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard systemic treatment for advanced lung cancer
Study: NCT06789029
Drug: perineural Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Erector Spinae Plane Block with 0.2% Ropivacaine + 0.1mg/kg perineural Dexamethasone
Study: NCT06789029
Drug: intravenous Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Erector Spinae Plane Block with 0.2% Ropivacaine + 0.1mg/kg intravenous Dexamethasone
Study: NCT06785662
Drug: The budesonide nasal irrigation
Normalized name: budesonide Nasal Spray
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The participant in this group used a solution containing 1 milligram of budesonide mixed with 240 milliliters of normal saline in a squeeze bottle (Cleanoze®) for nasal irrigation. The procedure will be performed once daily while leaning slightly forward over a sink.
Study: NCT06785662
Drug: The budesonide nasal spray
Normalized name: budesonide Nasal Spray
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The participants in this group used a nasal spray containing 64 micrograms of budesonide per spray, with two sprays per nostril administered twice daily (morning and evening).
Study: NCT06467357
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard of care chemotherapy by intravenous infusion
Study: NCT06467357
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard of care chemotherapy by intravenous infusion
Study: NCT06467357
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard of care immunotherapy by intravenous infusion
Study: NCT06467357
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Experimental therapy by intravenous infusion
Study: NCT06467357
Drug: Rilvegostomig
Normalized name: Rilvegostomig
DrugBank: Rilvegostomig (DB18991)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental therapy by intravenous infusion
Study: NCT05552326
Drug: Olezarsen
Normalized name: Olezarsen
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olezarsen will be administered by SC injection.
Study: NCT05768360
Drug: Savolitinib
Normalized name: savolitinib
DrugBank: Savolitinib (DB12048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will receive single dose of oral film-coated tablet of Savolitinib A dose on Day 1 of Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
Study: NCT06799195
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus is started on day +5 with a loading dose of 6 mg, followed by a maintenance dose of 2 mg daily, adjusted to target trough levels of 8-12 ng/mL. Sirolimus taper is recommended to start at day +90 and to be completed by day +180, provided there is no evidence of acute GVHD.
Study: NCT06799195
Drug: Mycophenolate Mofetil (MMF)
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MMF is started on day +5 at a dose of 15 mg/kg per dose (maximum 1 g per dose) three times daily. MMF is generally discontinued by day +35 in the absence of GVHD.
Study: NCT06318403
Drug: Transdermal estrogen
Normalized name: estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients will receive patches with identical labeling from our pharmacy, to be applied twice weekly. In the study group, these will contain 0.025 mg/day of estradiol. In the control group, these will be placebo. These will be applied twice weekly for three months beginning at the time of surgery and extending for three months after surgery.
Study: NCT06100237
Drug: Teclistamab
Normalized name: Teclistamab
DrugBank: Teclistamab (DB16655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teclistamab will be administered by subcutaneous (SC) injection per discretion of treating physician. Participants will receive the recommended dosage.
Study: NCT06100237
Drug: Talquetamab
Normalized name: Talquetamab
DrugBank: Talquetamab (DB16678)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talquetamab will be administered per discretion of treating physician. Participants will receive the recommended dosage.
Study: NCT06100237
Drug: Daratumumab SC
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab SC will be administered by subcutaneous (SC) injection per discretion of treating physician. Participants will receive the recommended dosage.
Study: NCT06782724
Drug: Psilocybin therapy
Normalized name: Monistat Simple Therapy
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin therapy consisting of three preparation, two dosing, and three integration sessions. All sessions will take place in a controlled, safety environment and supported by two study therapists
Study: NCT04978597
Drug: Opicapone 50 mg
Normalized name: opicapone 50 MG
DrugBank: Opicapone (DB11632)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Capsule, 50 mg, Oral. Swallow whole with water, once daily at bedtime at least 1 hour after L-DOPA/DDCI
Study: NCT04708418
Drug: VLP-encapsulated TLR9 Agonist CMP-001
Normalized name: poly (lactide-co-glycolide)-polyethylene glycol nanoparticles encapsulating quercetin
DrugBank: Quercetin (DB04216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given SC or intratumorally
Study: NCT05583526
Drug: Ritlecitinib
Normalized name: Ritlecitinib
DrugBank: Ritlecitinib (DB14924)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg capsule
Study: NCT06784570
Drug: levosemindan
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In common practice the loading dose is omitted as it is associated with hypotension.9 Usual dose range: 0.05 to 0.2 microg/kg/min. Dose based on actual body weight up to a maximum of 120 kg.5 Commence infusion at 0.05 microg/kg/min. If the initial rate is tolerated, consider increasing the maintenance rate to 0.1 microg/kg/min after 60 minutes. If the patient remains haemodynamically stable, further increase the dose to 0.2 microg/kg/min for the remainder of the infusion.
Study: NCT06791070
Drug: Disitamab Vedotin combined with Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disitamab Vedotin at a dosage of 2mg/kg and 3mg/kg of Toripalimab administered intravenously every 3 weeks (ivgtt q3w) is continued until disease progression, with the allowance for treatment discontinuation due to disease progression, death, intolerable toxicity, withdrawal of informed consent, initiation of new antineoplastic therapy, or other reasons specified in the protocol, with the earliest occurring event taking precedence. Alternatively, the study investigator may determine the need to discontinue treatment.
Study: NCT05768360
Drug: Digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The subjects will receive single dose of oral uncoated tablet of Digoxin Dose B on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
Study: NCT05768360
Drug: Metformin Hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The subjects will receive single dose of oral film-coated tablet of Metformin Hydrochloride Dose D on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
Study: NCT06788470
Drug: MSC
Normalized name: adMSC
DrugBank: Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins (DB15729)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratracheal administration of umbilical cord-derived mesenchymal stem cells (MSCs).
Study: NCT06784752
Drug: Octreotide LAR
Normalized name: octreotide LAR 20 MG Injection
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Octreotide LAR will be administered Q8W when co-administered with \[177Lu\]Lu-DOTA-TATE in the investigational arm followed by Q4W.~In the control arm Octreotide LAR will be administered Q4W.
Study: NCT05509400
Drug: Rimegepant
Normalized name: RIMEGEPANT
DrugBank: Rimegepant (DB12457)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DB Phase: Rimegepant 75 mg Orally Disintegrating Tablet (ODT)
Study: NCT05509400
Drug: Rimegepant
Normalized name: RIMEGEPANT
DrugBank: Rimegepant (DB12457)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OLE Phase: Rimegepant 75 mg ODT in association with each of the first 5 qualifying migraines
Study: NCT06787885
Drug: Levofloxacin + cefipime
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group 2
Study: NCT05768360
Drug: Furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The subjects will receive single dose of oral solution of Furosemide Dose C on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
Study: NCT06118021
Drug: HS-20094
Normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06441643
Drug: AR-17043 Ophthalmic Solution
Normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational monotherapy supplied in three concentration levels: low, medium, high
Study: NCT06441643
Drug: Latanoprost 0.005% Ophthalmic Solution
Normalized name: Latanoprost 0.005% Ophthalmic Solution
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Marketed monotherapy
Study: NCT06441643
Drug: Netarsudil 0.02% Ophthalmic Solution
Normalized name: Netarsudil 0.02% Ophthalmic Solution
DrugBank: Netarsudil (DB13931)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Marketed monotherapy
Study: NCT06441643
Drug: Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Marketed fixed dose combination
Study: NCT06441643
Drug: AR-17043 Vehicle
Normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT05079919
Drug: Olezarsen
Normalized name: Olezarsen
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olezarsen will be administered by SC injection.
Study: NCT04539236
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered daily by mouth on a 21 day cycle. Doses will be administered at 2.5 mg, 5 mg and 10 mg.
Study: NCT04539236
Drug: Luspatercept
Normalized name: Luspatercept
DrugBank: Luspatercept (DB12281)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered subcutaneously in the upper arm, thigh and/or abdomen on Day 1 of a 21 day cycle. Starting dose will be at 1.0 mg/kg and can be titrated, dependent on participant response, to doses of 1.33 mg/kg, and 1.75 mg/kg.
Study: NCT06784193
Drug: OP-3136
Normalized name: OP-1
DrugBank: Eptotermin alfa (DB11631)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: OP-3136
Study: NCT06789861
Drug: TT5
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Direct Intravenous administration of TT5 (5 ascending doses in Single Ascending Dose Part and 3 ascending doses administered during 7 days in Multiple Ascending Dose Part in healthy volunteers) Direct Intravenous administration of TT5 in surgical patients (4 doses administered on the same day) in surgical patients
Study: NCT05568537
Drug: Pylarify Piflufolastat Flourine-18 (18F-DCFPyL)
Normalized name: PIFLUFOLASTAT F-18
DrugBank: Piflufolastat F 18 (DB14805)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piflufolastat F18 will first be given intravenously over about 5 seconds.
Study: NCT05254002
Drug: Finerenone (BAY94-8862 ) 10 mg
Normalized name: Finerenone
DrugBank: Finerenone (DB16165)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: oral administration, once daily if screening eGFR (Estimated glomerular filtration rate) results are: \<60 mL/min/1.73 m2
Study: NCT05254002
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: oral administration, once daily
Study: NCT05254002
Drug: Empagliflozin Placebo
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Matching placebo to empagliflozin oral administration, once daily
Study: NCT05254002
Drug: Finerenone (BAY94-8862 ) 20 mg
Normalized name: Finerenone
DrugBank: Finerenone (DB16165)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: oral administration, once daily if screening eGFR (Estimated glomerular filtration rate) results are: ≥60 mL/min/1.73 m2
Study: NCT05254002
Drug: Finerenone Placebo
Normalized name: Finerenone
DrugBank: Finerenone (DB16165)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Matching Placebo to Finerenone oral administration once daily
Study: NCT05734066
Drug: Lurbinectedin
Normalized name: LURBINECTEDIN
DrugBank: Lurbinectedin (DB12674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as intravenous (IV) infusion once every 3 weeks (Q3W)
Study: NCT06246916
Drug: fianlimab
Normalized name: Fianlimab
DrugBank: Fianlimab (DB18858)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) administration every 3 weeks (Q3W) in combination with cemiplimab